United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - maprotiline hydrochloride (unii: 7c8j54pvfi) (maprotiline - unii:2u1w68trof) - maprotiline hydrochloride 25 mg - maprotiline hydrochloride tablets are indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic depressive illness, depressed type (major depressive disorder). maprotiline is also effective for the relief of anxiety associated with depression. maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. it should not be given concomitantly with monoamine oxidase (mao) inhibitors. a minimum of 14 days should be allowed to elapse after discontinuation of mao inhibitors before treatment with maprotiline is initiated. effects should be monitored with gradual increase in dosage until optimum response is achieved. the drug is not recommended for use during the acute phase of myocardial infarction.

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - arginine hydrochloride 5% - solution for infusion - 5 % - active: arginine hydrochloride 5% excipient: purified water - arginine hydrochloride 5% is indicated for the evaluation of pituitary growth hormone reserve.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arginine hydrochloride, quantity: 600 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : arginine stimulates the release of growth hormone by the pituitary gland and may be used instead of , or in addition to, other tests such as insulin-induced hypoglycaemia, for the evaluation of growth disorders; false positive and false negative results are relatively common and evaluation therefore should not be made on the basis of a single arginine test. arginine is used as an acidifying agent in severe metabolic alkalosis. arginine is used in some conditions accompanied by hyperammonaemia stemming from inborn errors of the urea cycle, particularly where there is a severe deficiency of ornithine carbamoyl transferase or carbamoyl phosphate synthetase where respiratory alkalosis is present.

Canada - English - Health Canada

teva canada limited - maprotiline hydrochloride - tablet - 75mg - maprotiline hydrochloride 75mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

teva canada limited - maprotiline hydrochloride - tablet - 50mg - maprotiline hydrochloride 50mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

teva canada limited - maprotiline hydrochloride - tablet - 25mg - maprotiline hydrochloride 25mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

novopharm limited - maprotiline hydrochloride - tablet - 10mg - maprotiline hydrochloride 10mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

pharmascience inc - maprotiline hydrochloride - tablet - 10mg - maprotiline hydrochloride 10mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

pharmascience inc - maprotiline hydrochloride - tablet - 25mg - maprotiline hydrochloride 25mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - English - Health Canada

pharmascience inc - maprotiline hydrochloride - tablet - 50mg - maprotiline hydrochloride 50mg - tricyclics and other norepinephrine-reuptake inhibitors